-
2024-513676-18-00
5
Transthyretin Amyloidosis
-
2024-519655-28-00
5
Premenopausal patients with high-risk HR-positive/HER2-negative breast
-
2024-520218-23-00
10
Pulmonary Arterial Hypertension
-
2025-520554-11-00
5
Cardiovascular Disease
-
2025-521563-13-01
4
Paediatric myopia
-
2025-522145-21-00
5
Metastatic hormone sensitive prostate cancer
-
2025-523544-12-00
5
Myelodysplastic neoplasms/syndromes (MDS)
-
2025-523576-23-00
5
Unresectable Stage III non-small cell lung cancer without progression
-
2025-523877-40-00
4
Endometrial adenocarcinoma
-
2024-518858-17-00
4
2026-05-22
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
-
2025-520466-22-00
5
2026-04-29
Advanced Platinum-resistant Epithelial Ovarian Cancer
-
2025-522512-16-00
3
2026-04-23
Metastatic Castration Resistant Prostate Cancer (mCRPC)
-
2025-523686-15-00
1
2026-04-08
Advanced or Metastatic Solid Tumors
-
2025-522767-15-00
5
2026-01-27
Acute Myeloid Leukemia
-
2025-521514-26-00
5
2026-01-26
Persistent, Recurrent, or Newly Diagnosed Metastatic Cervical Cancer W
-
2024-518007-22-00
5
2025-12-05
Prevention of monkeypox (mpox) infection
-
2024-512753-24-00
5
2025-08-05
Acute Myeloid Leukemia (AML)
-
2024-517500-11-00
7
2025-07-15
Colorectal Cancer
-
2024-512733-32-00
5
2025-03-31
Acute Myeloid Leukemia (AML)
-
2024-515451-38-00
5
2025-02-27
Primary Immune thrombocytopenia (ITP)
-
2023-507536-21-00
7
2024-10-04
Advanced Solid Tumors
-
2023-504231-41-01
10
2024-10-02
Locally advanced or metastatic urothelial cancer
-
2023-504918-29-00
5
2024-08-22
Hormone receptor positive breast cancer
-
2022-501105-12-00
5
2024-07-15
Urothelial Carcinoma